Want to see XNCR full AI Analyst Report?

Xencor (XNCR) Stock Forecast & Price Target

374 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XNCR Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Xencor

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XNCR Stock 12 Month Forecast

Average Price Target

$40.40

▲(42.05% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $40.40 with a high forecast of $46.00 and a low forecast of $26.00. The average price target represents a 42.05% change from the last price of $28.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","47":"$47","19.25":"$19.25","28.5":"$28.5","37.75":"$37.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,19.25,28.5,37.75,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,26.403076923076924,28.036153846153844,29.66923076923077,31.302307692307693,32.93538461538461,34.568461538461534,36.20153846153846,37.83461538461538,39.4676923076923,41.10076923076923,42.73384615384616,44.36692307692307,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,25.97230769230769,27.174615384615386,28.376923076923077,29.57923076923077,30.78153846153846,31.98384615384615,33.18615384615384,34.38846153846154,35.590769230769226,36.793076923076924,37.995384615384616,39.19769230769231,{"y":40.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.77,24.864615384615384,24.959230769230768,25.053846153846152,25.14846153846154,25.243076923076924,25.337692307692308,25.432307692307692,25.526923076923076,25.62153846153846,25.716153846153848,25.810769230769232,25.905384615384616,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.21,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.91,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$46.00

Average Price Target$40.40

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Derek Archila

Wells Fargo

$30→$44

Buy

54.71%

Upside

Assigned

10/27/26

Xencor (XNCR) Gets a Buy from Wells Fargo

Gregory Renza

Truist Financial

$29→$40

Buy

40.65%

Upside

Reiterated

10/27/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Xencor (NASDAQ: XNCR) and Incyte (NASDAQ: INCY)

David Nierengarten

Wedbush

$30→$45

Buy

58.23%

Upside

Assigned

10/27/26

Wedbush Keeps Their Buy Rating on Xencor (XNCR)

John Newman

Canaccord Genuity

$38

Buy

33.61%

Upside

Reiterated

10/27/26

Canaccord Genuity Keeps Their Buy Rating on Xencor (XNCR)

Etzer Darout

Barclays

$35→$45

Buy

58.23%

Upside

Reiterated

10/26/26

Xencor price target raised to $45 from $35 at BarclaysXencor price target raised to $45 from $35 at Barclays

Leonid Timashev

RBC Capital

$20→$43

Buy

51.20%

Upside

Reiterated

10/26/26

RBC Capital Remains a Buy on Xencor (XNCR)

Brian Cheng

J.P. Morgan

―

Hold

―

Reiterated

10/26/26

Xencor Maintained at Hold as Strong Early XmAb819 Data Offset by Execution and Clinical Risk

Alec Stranahan

Bank of America Securities

$26

Hold

-8.58%

Downside

Reiterated

10/26/26

Xencor (XNCR) Receives a Hold from Bank of America Securities

Sean McCutcheon

Raymond James

$46

Buy

61.74%

Upside

Assigned

09/01/26

Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James

Steven Seedhouse

Cantor Fitzgerald

$44

Buy

54.71%

Upside

Reiterated

08/10/26

Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)

Edward Tenthoff

Piper Sandler

$33

Buy

16.03%

Upside

Reiterated

08/06/26

Piper Sandler Remains a Buy on Xencor (XNCR)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/26

Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/05/26

Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Derek Archila

Wells Fargo

$30→$44

Buy

54.71%

Upside

Assigned

10/27/26

Xencor (XNCR) Gets a Buy from Wells Fargo

Gregory Renza

Truist Financial

$29→$40

Buy

40.65%

Upside

Reiterated

10/27/26

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Xencor (NASDAQ: XNCR) and Incyte (NASDAQ: INCY)

David Nierengarten

Wedbush

$30→$45

Buy

58.23%

Upside

Assigned

10/27/26

Wedbush Keeps Their Buy Rating on Xencor (XNCR)

John Newman

Canaccord Genuity

$38

Buy

33.61%

Upside

Reiterated

10/27/26

Canaccord Genuity Keeps Their Buy Rating on Xencor (XNCR)

Etzer Darout

Barclays

$35→$45

Buy

58.23%

Upside

Reiterated

10/26/26

Xencor price target raised to $45 from $35 at BarclaysXencor price target raised to $45 from $35 at Barclays

Leonid Timashev

RBC Capital

$20→$43

Buy

51.20%

Upside

Reiterated

10/26/26

RBC Capital Remains a Buy on Xencor (XNCR)

Brian Cheng

J.P. Morgan

―

Hold

―

Reiterated

10/26/26

Xencor Maintained at Hold as Strong Early XmAb819 Data Offset by Execution and Clinical Risk

Alec Stranahan

Bank of America Securities

$26

Hold

-8.58%

Downside

Reiterated

10/26/26

Xencor (XNCR) Receives a Hold from Bank of America Securities

Sean McCutcheon

Raymond James

$46

Buy

61.74%

Upside

Assigned

09/01/26

Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James

Steven Seedhouse

Cantor Fitzgerald

$44

Buy

54.71%

Upside

Reiterated

08/10/26

Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)

Edward Tenthoff

Piper Sandler

$33

Buy

16.03%

Upside

Reiterated

08/06/26

Piper Sandler Remains a Buy on Xencor (XNCR)

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/06/26

Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

08/05/26

Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OMCLOmnicell

PVLAPalvella Therapeutics

ZVRAZevra Therapeutics

STOKStoke Therapeutics

AMRXAmneal Pharmaceuticals

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xencor

3 Months

David NierengartenWedbush

Success Rate

8/12 ratings generated profit

Average Return

+18.07%

Copying David Nierengarten's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +18.07% per trade.

1 Year

Matt PhippsWilliam Blair

Success Rate

11/11 ratings generated profit

Average Return

+81.22%

Copying Matt Phipps's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +81.22% per trade.

2 Years

Matt PhippsWilliam Blair

Success Rate

11/11 ratings generated profit

Average Return

+124.73%

Copying Matt Phipps's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +124.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XNCR Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XNCR has received 25 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. XNCR average Analyst price target in the past 3 months is 40.40.

Each month's total comprises the sum of three months' worth of ratings.

XNCR Financial Forecast

XNCR Earnings Forecast

Next quarter’s earnings estimate for XNCR is -$0.33 with a range of -$1.21 to $0.22. The previous quarter’s EPS was -$0.29. XNCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XNCR has Performed in-line its overall industry.

XNCR Sales Forecast

Next quarter’s sales forecast for XNCR is $63.00M with a range of $3.12M to $115.20M. The previous quarter’s sales results were $51.22M. XNCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XNCR has Performed in-line its overall industry.

XNCR Stock Forecast FAQ

What is XNCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Xencor Inc’s 12-month average price target is 40.40.

What is XNCR’s upside potential, based on the analysts’ average price target?

Xencor Inc has 42.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is XNCR a Buy, Sell or Hold?

Xencor Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Xencor Inc’s price target?

The average price target for Xencor Inc is 40.40. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $46.00 ,the lowest forecast is $26.00. The average price target represents 42.05% Increase from the current price of $28.44.

What do analysts say about Xencor Inc?

Xencor Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of XNCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Xencor (XNCR) Stock Forecast & Price Target

XNCR Analyst Ratings

XNCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Xencor

XNCR Analyst Recommendation Trends

XNCR Financial Forecast

XNCR Earnings Forecast

XNCR Sales Forecast

XNCR Stock Forecast FAQ

Detailed List of Analyst Forecasts